Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05820685 · ClinicalTrials.gov registry record · Phase 4
Dronabinol On the Pain Experience
A Phase 4 study, sponsored by The University of Texas Health Science Center, Houston.
- Terminated
- Registry status
- Phase 4
- Development phase
- 484
- Enrollment target
NCT05820685 is a Phase 4 study that was terminated before completion, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 484 participants.
The verdict
NCT05820685, a Phase 4 study, was terminated before completion, sponsored by The University of Texas Health Science Center, Houston.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 484 participants
- Enrollment target
Study Summary
The purpose of this study is to identify the effect dronabinol has on opioid exposure when used as an adjunct to the current standard multi-modal pain regimen (MMPR)
Interventions
- DRUG Dronabinol
- DRUG Standard of Care (acetaminophen +naproxen +gabapentin + as needed oxycodone or Tramadol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 484 participants |
| Start Date | 2023-07-27 |
| Est. Completion | 2024-04-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05820685
The ClinicalTrials.gov registry entry for NCT05820685 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 484 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dronabinol is the first listed.
NCT05820685 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05820685 about?
NCT05820685 is a clinical study titled "Dronabinol On the Pain Experience". The purpose of this study is to identify the effect dronabinol has on opioid exposure when used as an adjunct to the current standard multi-modal pain regimen (MMPR)
What is the current status of trial NCT05820685?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 484 participants. The study started on 2023-07-27. Estimated completion is 2024-04-29.
What interventions are being tested in trial NCT05820685?
The interventions under investigation include: Dronabinol (DRUG), Standard of Care (acetaminophen +naproxen +gabapentin + as needed oxycodone or Tramadol) (DRUG).
Who is sponsoring clinical trial NCT05820685?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.